Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis

This competitive intelligence report about GPC3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting glypican-3 (GPC3) as of July of 2025.

GPC3, a GPI-anchored cell surface heparan sulfate proteoglycan, is an attractive target for hepatocellular carcinoma (HCC) immunotherapy because it is selectively expressed on HCC and promotes HCC cell growth and migration. GPC3 is rarely or not expressed in normal liver tissues, making it a perfect diagnostic and treatment target for HCC.

Liver cancer is the second leading cause of cancer-related deaths, and hepatocellular carcinoma is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican-3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis.

GPC3 has been demonstrated as a viable target for CAR T-cell and NK cell therapy, T-cell and NK cell engaging bispecific antibodies, immune checkpoint bispecific antibodies, antibody-drug conjugates, radiopharmaceuticals and even vaccines while naked antibodies are of low interest. More than 20 product candidates are in clinical development and further eight at IND or IND-enabling stage.

This product consists of a competitor description and analysis in a tabular format provided as a pdf document which is sent by e-mail within one day, usually within one hour. The pdf report includes a compilation of active projects in research and development of GPC3-targeted product candidates.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis reports:
Competitor Analysis reports deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced with hyperlinks to the source of information.